This methodological development for assaying plasma NfL has stimulated potential opportunities for large-scale applications in clinical practice and in randomized clinical trials as a method for identifying patients at risk for dementias, including Alzheimer’s disease (AD) [3]. The gene discussed is NEFL; the disease is early-onset autosomal dominant Alzheimer disease.